{
    "title": "Regeneron beats profit view, to end antibody deal with Sanofi",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4756986/Regeneron-profit-blows-past-estimates.html",
    "date": "2017-08-03",
    "keywords": [
        "regeneron",
        "dupixent",
        "grover",
        "year",
        "growth",
        "treatment",
        "sanofi",
        "eylea",
        "profit",
        "demand",
        "drug",
        "end",
        "eye",
        "percent",
        "thursday",
        "antibody",
        "discovery",
        "deal",
        "quarter",
        "ag",
        "kevzara",
        "market",
        "agreement",
        "flagship",
        "sa",
        "forecast",
        "cfra",
        "researchs",
        "jeffrey",
        "loo",
        "drugmaker",
        "rampd",
        "funding",
        "degeneration",
        "vision",
        "loss",
        "beat",
        "position",
        "competition",
        "lucentis",
        "roche",
        "novartis",
        "percentage",
        "biotech",
        "eczema",
        "arthritis",
        "reliance",
        "partner",
        "week",
        "euros",
        "adoption",
        "access",
        "approval",
        "trial",
        "asthma",
        "expiration",
        "plethora",
        "pipeline",
        "potential",
        "cancer",
        "immunotherapy",
        "regn2810",
        "tax",
        "rate",
        "dollar",
        "thomson",
        "revenue",
        "reporting",
        "divya",
        "editing",
        "koyyur",
        "supriya",
        "kurane",
        "maju",
        "samuel"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}